Hormone replacement therapy lowers plasma Lp(a) concentrations: Comparison of cyclic transdermal and continuous estrogen-progestin regimens

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1215-1221

  Taskinen, Marja Riitta ^a   Puolakka, J ^b   Pyorala T ^c   Luotola, H ^c   Bjorn M ^d,e   Kaariainen J ^f   Lahdenpera S ^a   Ehnholm, C ^f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Department of Medicine   (Finland)

^c Gyne Praxis   (Finland)

^d NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^e Yla Savon terveydenhuollon kuntayhtyma   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

HDL cholesterol; hormone replacement therapy; LDL cholesterol; lipoprotein(a); postmenopause

Indexed keywords

APOLIPOPROTEIN B; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029793964     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1215     Document Type: Article

References (62)

1. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
2. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann N Y Acad Sci. 1990;592:193-203.
3. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci. 1990;592:263-271.
4. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 1991;325:756-762.
5. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
6. Belchetz PE. Hormonal therapy of postmenopausal women. N Engl J Med. 1994;330:1062-1071.
7. Seed M, Crook D. Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol. 1994;5:48-58.
8. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
9. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338:274-277.
10. Mattsson L-Å, Samsioe G. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen, Acta Obstet Gynecol Scand. 1985;130(suppl):53-58.
11. Obel EB, Munk-Jensen N, Svenstrup B, Bennett P, Micic S, Henrik-Nielsen R, Pors Nielsen S, Gydesen H, Jensen BM. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas. 1993;16:13-21.
12. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Melab. 1991;73:925-930.
13. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu K, Szklo M, for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
14. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
15. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-2216.
16. Utermann G. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. Curr Opin Lipidol. 1990;1:404-410.
17. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 1991;115:209-218.
18. Sandholzer C. Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
19. Budde T, Fechtrup C, Bösenberg E, Vielhauer C, Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14:1730-1736.
20. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-235.
21. Kraft HG, Sandholzer C, Menzel HJ, Utermann G. Apolipoprotein(a) alleles determine lipoprotein(a) particle density and concentration in plasma. Arterioscler Thromb. 1992;12:302-306.
22. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
23. Berglund L. Diet and drug therapy for lipoprotein(a). Curr Opin Lipidol. 1995;6:48-56.
24. Selby JV, Austin MA, Sandholzer C, Quesenberry CP, Zhang D, Mayer E, Utermann G. Environmental and behavioral influences on plasma lipoprotein(a) concentration in women twins. Prev Med. 1994;23:345-353.
25. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991;37:1950-1954.
26. Meilhahn EN, Kuller LH, Matthews KA, Stein EA. Lp(a) concentrations among pre- and postmenopausal women over time: the Healthy Women Study. Circulation. 1991;84(suppl II):II-2170. Abstract.
27. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. Br Med J. 1991;303:694.
28. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 1994;154:1106-1110.
29. Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Ghanem K, Gaubatz J, Morrisett JD. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women. Lancet. 1991;337:612.
30. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ. Post-menopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med. 1994;123:837-841.
31. Kim CJ, Jang C, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275-281.
32. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1979;60:427-439.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
34. Demacker PNM, Vos-Janssen HE, Hijmans AGM, van't Laar A, Jansen AP. Measurement of high-density lipoprotein cholesterol in serum: comparison of six isolation methods combined with enzymic cholesterol analysis. Clin Chem. 1980;26:1779-1786.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
36. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
37. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem. 1984;137:335-343.
38. Mertens R, Liedtke RJ, Batjer JD. Evaluation of a radioimmunoassay for estradiol in unextracted serum. Clin Chem. 1983;29:1961-1963.
39. Hemmilä I. Fluoroimmunoassays and immunofluorometric assays. Clin Chem. 1985;31:359-370.
40. Gotto AM. Postmenopausal hormone-replacement therapy, plasma lipoprotein(a), and risk for coronary heart disease. J Lab Clin Med. 1994;123:800-803.
41. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994;14:1586-1593.
42. Rader DJ, Mann WA, Cain W, Kraft H-G, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403-1408.
43. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990;85:1542-1547.
44. Knight BL, Perombelon YFN, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991;87:227-237.
45. Rader DJ, Cain W, Zech LA, Usher D, Brewer B. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein (a) production. J Clin Invest. 1993;91:443-447.
46. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer B. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to difference in production rate. J Clin Invest. 1994;93:2758-2763.
47. Marcovina S, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipidol. 1995;6:136-145.
48. Lahdenperä S, Puolakka J, Pyörälä T, Luotola H, Taskinen M-R. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. Atherosclerosis. 1996;122:153-162.
49. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 1994;5:236-240.
50. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 1992;166:950-955.
51. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler JE, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol. 1991;77:235-240.
52. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746-750.
53. Walsh BW, Schiff S, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
54. Whitehead MI, Fraser D, Schenkel L, Crook D, Stevenson JC. Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet. 1990;335:310-312.
55. Cortellaro M, Nencioni T, Boschetti C, Ortolani S, Buzzi F, Francucci B, Caraceni MP, Abelli P, Polvani F, Zanussi C. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment. Eur J Clin Pharmacol. 1991;41:555-559.
56. Tufecki M, Colak Z, Ozan H, Kimya Y, Aydinlar A. Effect of progestogens on estrogen-induced lipoprotein changes. Eur J Obstet Gynecol Reprod Biol. 1993;49:169-174.
57. Slowinska-Srzednicka J, Zgliczynski S, Chotkowska E, Srzednicki M, Stopinska-Gluszak U, Jeske W, Brzezinska A, Zgliczynski W, Sadowski Z. Effects of transdermal 17β-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women. J Intern Med. 1993;234:447-451.
58. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994;35:2083-2093.
59. Jensen J, Juel Riis B, Strom, Christiansen C. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol. 1987;94:130-135.
60. Christiansen C, Juel Riis B. Five years with continuous combined oestrogen/progestogen therapy: effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol. 1990;97:1087-1092.
61. Newnham HH. Oestrogens and atherosclerotic vascular disease: lipid factors. Bailliere's Clin Endocrinol Metab. 1993;7:61-90.
62. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.